Biotech startup Myria combines synthetic biology, AI and super-speed screening methods to develop complex drugs for a plethora of diseases. The new funding will enable Myria to expand its scientific team, kick-start its internal drug candidate pipeline, and forge additional partnerships with leading pharmaceutical companies.
